GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Abroad (travel likely)Active Not RecruitingPHASE1, PHASE2

Conditions

HCC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Johns Hopkins Hospital, Baltimore, Maryland, United States
  • Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Auckland Clinical Studies, Auckland, New Zealand